BTA biota holdings limited

new cdc guidelines should boost revenue, page-7

  1. 3,045 Posts.
    Nah, Avexa's product is way too advanced in trial... Biota adds value in the very early stages of development, they would take significant risk trying to run late stage trials themselves or market drugs directly. I would prefer buying a new platform, perhaps even Novogen. DNDN has seen success in trials, that would be another area to look at.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.